FDG PET-CT as an important diagnostic tool and prognostic marker in suspected recurrent cervical carcinoma after radiotherapy: comparison with MRI.
MRI
PET-CT
progression-free survival
recurrence
sensitivity and specificity
uterine cervical neoplasms
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
received:
18
04
2022
accepted:
15
09
2022
pubmed:
2
11
2022
medline:
15
12
2022
entrez:
1
11
2022
Statut:
epublish
Résumé
Recurrent disease in post-irradiation patients with cervical cancer is often difficult to delineate on magnetic resonance imaging (MRI), because posttreatment changes can have a similar appearance, and further evaluation is often required. The aims of the study were to evaluate positron emission tomography/computed tomography with 18F-fluorodeoxyglucose (FDG PET-CT) diagnostic role in suspected recurrent cervical cancer after radiotherapy, compare it to MRI, and assess their prognostic impact in these patients. This cohort retrospective study included patients previously treated with radiotherapy for carcinoma of uterine cervix with suspected recurrence, who had undergone MRI of abdomen and pelvis, and were subsequently evaluated on FDG PET-CT, with minimum follow-up period of 12 months. In the total of 84 patients included in analysis, MRI FDG PET-CT represents useful diagnostic tool in suspected recurrent cervical cancer after radiotherapy, showing high sensitivity in its detection. In addition, it is an independent factor in predicting progression-free survival in these patients.
Sections du résumé
BACKGROUND
Recurrent disease in post-irradiation patients with cervical cancer is often difficult to delineate on magnetic resonance imaging (MRI), because posttreatment changes can have a similar appearance, and further evaluation is often required. The aims of the study were to evaluate positron emission tomography/computed tomography with 18F-fluorodeoxyglucose (FDG PET-CT) diagnostic role in suspected recurrent cervical cancer after radiotherapy, compare it to MRI, and assess their prognostic impact in these patients.
PATIENTS AND METHODS
This cohort retrospective study included patients previously treated with radiotherapy for carcinoma of uterine cervix with suspected recurrence, who had undergone MRI of abdomen and pelvis, and were subsequently evaluated on FDG PET-CT, with minimum follow-up period of 12 months.
RESULTS
In the total of 84 patients included in analysis, MRI
CONCLUSION
FDG PET-CT represents useful diagnostic tool in suspected recurrent cervical cancer after radiotherapy, showing high sensitivity in its detection. In addition, it is an independent factor in predicting progression-free survival in these patients.
Identifiants
pubmed: 36317553
pii: raon-2022-0042
doi: 10.2478/raon-2022-0042
pmc: PMC9784362
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
453-460Informations de copyright
© 2022 Milica Stojiljkovic, Dragana Sobic Saranovic, Strahinja Odalovic, Marina Popovic, Jelena Petrovic, Nevena Rankovic, Milos Veljkovic, Vera Artiko, published by Sciendo.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-49. doi: 10.3322/caac.21669
doi: 10.3322/caac.21669
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet 2018; 143(Suppl 2): S22-36. doi: 10.1002/ijgo.13865
doi: 10.1002/ijgo.13865
Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 95(Suppl 1): S43-103. doi: 10.1016/S0020-7292(06)60030-1
doi: 10.1016/S0020-7292(06)60030-1
Thomas GM, Dembo AJ, Myhr T, Black B, Pringle JF, Rawlings G. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery. Int J Gynecol Cancer 1993; 3: 193-8. doi: 10.1046/j.1525-1438.1993.03040193.x
doi: 10.1046/j.1525-1438.1993.03040193.x
Gandy N, Arshad MA, Park WE, Rockall AG, Barwick TD. FDG-PET Imaging in cervical cancer. Semin Nucl Med 2019; 49: 461-70. doi: 10.1053/j.semnu-clmed.2019.06.007.
doi: 10.1053/j.semnu-clmed.2019.06.007
Patel-Lippmann K, Robbins JB, Barroilhet L, Anderson B, Sadowski EA, Boyum J. MR imaging of cervical cancer. Magn Reson Imaging Clin N Am 2017; 25: 635-49. doi: 10.1016/j.mric.2017.03.007
doi: 10.1016/j.mric.2017.03.007
Palaniswamy SS, Borde CR, Subramanyam P. 18F-FDG PET/CT in the evaluation of cancer cervix: where do we stand today? Nucl Med Commun 2018; 39: 583-92. doi: 10.1097/MNM.0000000000000851
doi: 10.1097/MNM.0000000000000851
Vinh-Hung V, Bourgain C, Vlastos G, Cserni G, De Ridder M, Storme G et al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer 2007; 7: 164. doi:10.1186/1471-2407-7-164
doi: 10.1186/1471-2407-7-164
Cancer.Net. Cervical Cancer: Statistics. [Internet]. American Society of Clinical Oncology (ASCO); c2005-21. [cited 2021 Aug 17]. Available from: https://www.cancer.net/cancer-types/cervical-cancer/statistics
Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 2007; 110: 1738-44. doi: 10.1002/cncr.22974
doi: 10.1002/cncr.22974
Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol 2010; 28: 2108-13. doi: 10.1200/JCO.2009.25.4151
doi: 10.1200/JCO.2009.25.4151
Yen TC, See LC, Lai CH, Tsai CS, Chao A, Hsueh S, et al. Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. Eur J Nucl Med Mol Imaging 2008; 35: 493-501. doi: 10.1007/s00259-007-0612-1
doi: 10.1007/s00259-007-0612-1
Han S, Kim H, Kim YJ, Suh CH, Woo S. Prognostic value of volume-based metabolic parameters of 18F-FDG PET/CT in uterine cervical cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 2018; 211: 1112-21. doi: 10.2214/AJR.18.19734
doi: 10.2214/AJR.18.19734
Miccò M, Vargas HA, Burger IA, Kollmeier MA, Goldman DA, Park KJ, et al. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. Eur J Radiol 2014; 83: 1169-76. doi: 10.1016/j.ejrad.2014.03.024
doi: 10.1016/j.ejrad.2014.03.024
Ho JC, Allen PK, Bhosale PR, Rauch GM, Fuller CD, Mohamed AS, et al. Diffusion-weighted magnetic resonance imaging as a predictor of outcome in cervical cancer after chemoradiation. Int J Radiat Oncol Biol Phys 2017; 97: 546-53. doi: 10.1016/j.ijrobp.2016.11.015
doi: 10.1016/j.ijrobp.2016.11.015
Tavassoéli FA, Devilee P. IARC WHO classification of tumours, pathology and genetics tumours of the breast and female genital organs . Vol 4. 3rd edition. Lyon: IARC publications; 2003.
Kurman RJ, Hedrick-Ellenson L, Ronnett BM. Blaustein’s pathology of the female genital tract . 6th edition. New York: Springer; 2011.
Meads C, Davenport C, Małysiak S, Kowalska M, Zapalska A, Guest P, et al. Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation. BJOG 2014; 121: 398-407. doi: 10.1111/1471-0528.12460
doi: 10.1111/1471-0528.12460
Chu Y, Zheng A, Wang F, Lin W, Yang X, Han L, et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. Nucl Med Commun 2014; 35: 144-50. doi: 10.1097/MNM.0000000000000026
doi: 10.1097/MNM.0000000000000026
Pallardy A, Bodet-Milin C, Oudoux A, Campion L, Bourbouloux E, Sagan C, et al. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 2010; 37: 1270-8. doi: 10.1007/s00259-010-1417-1
doi: 10.1007/s00259-010-1417-1
Bjurberg M, Brun E. Clinical impact of 2-deoxy-2-[18F] fluoro-D-glucose (FDG)-positron emission tomography (PET) on treatment choice in recurrent cancer of the cervix uteri. Int J Gynecol Cancer 2013; 23: 1642-6. doi: 10.1097/IGC.0b013e3182a50537
doi: 10.1097/IGC.0b013e3182a50537
Lai CH, Huang KG, See LC, Yen TC, Tsai CS, Chang TC, et al. Restaging of recurrent cervical carcinoma with dual-phase [18F] fluoro-2-deoxy-D-glucose positron emission tomography. Cancer 2004; 100: 544-52. doi: 10.1002/cncr.11928
doi: 10.1002/cncr.11928
Yen TC, Lai CH, Ma SY, Huang KG, Huang HJ, Hong JH, et al. Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer. Eur J Nucl Med Mol Imaging 2006; 33: 1399-407. doi: 10.1007/s00259-006-0090-x
doi: 10.1007/s00259-006-0090-x
Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004; 22: 2167-71. doi: 10.1200/JCO.2004.09.035
doi: 10.1200/JCO.2004.09.035
Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007; 298: 2289-95. doi: 10.1001/jama.298.19.2289
doi: 10.1001/jama.298.19.2289
Kim YJ, Han S, Kim YS, Nam JH. Prognostic value of post-treatment 18F-fluorodeoxyglucose positron emission tomography in uterine cervical cancer patients treated with radiotherapy: a systematic review and meta-analysis. J Gynecol Oncol 2019; 30: e66. doi: 10.3802/jgo.2019.30.e66.
doi: 10.3802/jgo.2019.30.e66
Onal C, Guler OC, Reyhan M, Yapar AF. Long-term outcomes of cervical cancer patients with complete metabolic response after definitive chemoradiotherapy. J Gynecol Oncol 2021; 32: e74. doi: 10.1016/j.clon.2021.03.022
doi: 10.1016/j.clon.2021.03.022
Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, et al. Predictive role of post-treatment [18F] FDG PET/CT in patients with uterine cervical cancer. Eur J Radiol 2012; 81: e817-e822. doi: 10.1016/j.ejrad.2012.02.015
doi: 10.1016/j.ejrad.2012.02.015